Stereospecific disposition of fluvastatin in streptozotocin-induced diabetic rats

Canadian Journal of Physiology and Pharmacology

Volumn 80, Issue 11, 2002, Pages 1071-1075

  Rocha, Adriana ^a   Coelho, Eduardo Barbosa ^a   Lanchote, Vera Lucia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Enantiomers; Fluvastatin; Pharmacokinetics; Rats; Streptozotocin diabetes

Indexed keywords

FLUINDOSTATIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALCULATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENANTIOMER; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RANK SUM TEST; RAT; STEREOCHEMISTRY; STEREOSPECIFICITY; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; FATTY ACIDS, MONOUNSATURATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; RATS; RATS, WISTAR; STEREOISOMERISM;

EID: 0036904347     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y02-136     Document Type: Article

References (20)

1. Barnett, C.R., Flatt, P.R., and Ioannides, C. 1990. Induction of hepatic microsomal P450 I and IIB proteins by hyperketonaemia. Biochem. Pharmacol. 40: 393-397.
2. Beckman, J.A., Greager, M.A., and Libby, P. 2002. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. J. Am. Med. Assoc. 287: 2570-2581.
3. Costa, C., Pupo, C., Viscomi, G., Catania, S., Salemi, M., and Imperatore, C. 1999. Modifications in the metabolic pathways of benzene in streptozotocin-induced diabetic rat. Arch. Toxicol. 6: 301-306.
4. Dain, J.G., Fu, E., Gorski, J., Nicoletti, J., and Scallen, T.J. 1993. Biotransformation of fluvastatin sodium in humans. Drug Metab. Dispos. 21: 567-572.
5. Desager, J.-P., and Horsmans, Y. 1996. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet. 31: 348-371.
6. Emami, J., Pasutto, F.M., and Jamali, F. 1998. Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydrochloroquine enantiomers in rats. Pharm. Res. 15: 897-903.
7. Feillet-Coudray, C., Rock, E., Coudray, C., Grzelkowska, K., Azais-Braesco, V., Dardevet, D., and Mazur, A. 1999. Lipid peroxidation and antioxidant status in experimental diabetes. Clin. Chim. Acta, 284: 31-43.
8. Irizar, A., and Ioannides, C. 1995. Extrahepatic expression of P450 proteins in insulin-dependent diabetes mellitus. Xenobiotica, 25: 941-949.
9. Jensen, K., Christiansen, J.S., Asteven, A.K., and Parving, H.H. 1981. Renal function in Streptozocin diabetic rats. Diabetologia, 21: 409-414.
10. Lanchote, V.L., Rocha, A., Albuquerque, F.U.V., Coelho, E.B., and Bonato, P.S. 2001. Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. J. Chromatogr. B, 765: 81-88.
11. Scripture, C.D., and Pieper, A. 2001. Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet. 40: 263-281.
12. Shargel, L., and Yu, A.B.C. 1993. Applied Biopharmaceutics and Pharmacokinetics. Prentice-Hall International Inc., London. p. 625.
13. Shimojo, N. 1994. Cytochrome P450 changes in rats with streptozotocin-induced diabetes. Int. J. Biochem. 26: 1261-1268.
14. Shimojo, N., Ishizaki, T., Imaoka, S., Funae, Y., Fujii, S., and Okuda, K. 1993. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozotocin-induced diabetes. Biochem. Pharmacol. 46: 621-627.
15. TB (CYP2C9) by (±)-fluvastatin. Clin. Pharmacol. Ther. 58: 412-417.
16. Tse, F.L.S., and Labbadia, D. 1992. Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit. Biopharm. Drug Dispos. 13: 285-294.
17. Tse, F.L.S., Smith, H.T., Ballard, F.H., and Nicoletti, J. 1990. Disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in mouse, rat, dog, and monkey. Biopharm. Drug Dispos. 11: 519-531.
18. Tse, F.L.S., Nickerson, D.F., and Yardley, W.S. 1993. Binding of fluvastatin to blood cells and plasma proteins. J. Pharm. Sci. 82: 942-947.
19. Xiaotao, Q., and Hall, S.D. 1995. Enantioselective effects of experimental diabetes mellitus on the metabolism of ibuprofen. J. Pharmacol. Exp. Ther. 274: 1192-1198.
20. Zysset, T., and Sommer, L. 1986. Diabetes alters drug metabolism-In vivo studies in a streptozotocin-diabetic rat model. Experientia, 42: 560-562.